Levocarnitine tartrate

Biochem/physiol Actions MLR-1023 has a therapeutic potential to treat type 2 diabetes. MLR-1023 is a potent, orally active, allosteric activator of the non-receptor Src-related Lyn kinase that produces lasting glucose lowering, reduces HbA1c

General description Monopolar spindle 1 (Mps1) protein contains a TPR (tetratricopeptide repeat) motif at its N-terminal and a C-terminal kinase domain. Application Mps1-IN-3 has been used in 2D-proliferation and 3D-organotypic culture

Myricetin 3-O-β-D-Galactopyranoside.

Myricetin 3-O-β-D-Galactopyranoside.

An inhibitor of stearoyl-CoA desaturase that selectively eliminates hPSCs (EC₅₀ = 2 &microM) while sparing progenitor and differentiated cells developed as a strategy to prevent tumorigenic risk from residual undifferentiated cells used

An inhibitor of stearoyl-CoA desaturase that selectively eliminates hPSCs (EC₅₀ = 2 &microM) while sparing progenitor and differentiated cells developed as a strategy to prevent tumorigenic risk from residual undifferentiated cells used

An inhibitor of stearoyl-CoA desaturase that selectively eliminates hPSCs (EC₅₀ = 2 &microM) while sparing progenitor and differentiated cells developed as a strategy to prevent tumorigenic risk from residual undifferentiated cells used

An inhibitor of stearoyl-CoA desaturase that selectively eliminates hPSCs (EC₅₀ = 2 &microM) while sparing progenitor and differentiated cells developed as a strategy to prevent tumorigenic risk from residual undifferentiated cells used

General descriptionPoly(ethylene glycol) (PEG) is a non-ionic hydrophilic polymer and is available in different molecular weights. It facilitates the purification and crystal growth of proteins and nucleic acids. PEG and dextran together result in

Poly(L-lactide)

RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin ( HY-10219 ) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase

RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin ( HY-10219 ) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase